132 related articles for article (PubMed ID: 35621706)
21. 5-Fluorocytosine combined with Fcy-hEGF fusion protein targets EGFR-expressing cancer cells.
Lan KH; Shih YS; Chang CA; Yen SH; Lan KL
Biochem Biophys Res Commun; 2012 Nov; 428(2):292-7. PubMed ID: 23085230
[TBL] [Abstract][Full Text] [Related]
22. Photosensitizer-driven nanoassemblies of homodimeric prodrug for self-enhancing activation and synergistic chemo-photodynamic therapy.
Zhang S; Wang Z; Kong Z; Wang Y; Zhang X; Sun B; Zhang H; Kan Q; He Z; Luo C; Sun J
Theranostics; 2021; 11(12):6019-6032. PubMed ID: 33897896
[TBL] [Abstract][Full Text] [Related]
23. Annexin V-targeted enzyme prodrug therapy using cytosine deaminase in combination with 5-fluorocytosine.
Van Rite BD; Harrison RG
Cancer Lett; 2011 Aug; 307(1):53-61. PubMed ID: 21546157
[TBL] [Abstract][Full Text] [Related]
24. ROS triggered cleavage of thioketal moiety to dissociate prodrug nanoparticles for chemotherapy.
Pan Q; Deng X; Gao W; Chang J; Pu Y; He B
Colloids Surf B Biointerfaces; 2020 Oct; 194():111223. PubMed ID: 32615519
[TBL] [Abstract][Full Text] [Related]
25. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
[TBL] [Abstract][Full Text] [Related]
26. pH and ROS sequentially responsive podophyllotoxin prodrug micelles with surface charge-switchable and self-amplification drug release for combating multidrug resistance cancer.
Li C; Wang Y; Zhang S; Zhang J; Wang F; Sun Y; Huang L; Bian W
Drug Deliv; 2021 Dec; 28(1):680-691. PubMed ID: 33818237
[TBL] [Abstract][Full Text] [Related]
27. Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells.
Lan KH; Tsai CL; Chen YY; Lee TL; Pai CW; Chao Y; Lan KL
Biochem Biophys Res Commun; 2021 Dec; 582():137-143. PubMed ID: 34710829
[TBL] [Abstract][Full Text] [Related]
28. Reactive oxygen species-activated self-amplifying prodrug nanoagent for tumor-specific Cu-chelate chemotherapy and cascaded photodynamic therapy.
Chen J; Tan X; Huang Y; Xu C; Zeng Z; Shan T; Guan Z; Xu X; Huang Z; Zhao C
Biomaterials; 2022 May; 284():121513. PubMed ID: 35398586
[TBL] [Abstract][Full Text] [Related]
29. Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Chen SH; Sun JM; Chen BM; Lin SC; Chang HF; Collins S; Chang D; Wu SF; Lu YC; Wang W; Chen TC; Kasahara N; Wang HE; Tai CK
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32093290
[TBL] [Abstract][Full Text] [Related]
30. Light-activatable dual-source ROS-responsive prodrug nanoplatform for synergistic chemo-photodynamic therapy.
Yang B; Wang K; Zhang D; Sun B; Ji B; Wei L; Li Z; Wang M; Zhang X; Zhang H; Kan Q; Luo C; Wang Y; He Z; Sun J
Biomater Sci; 2018 Nov; 6(11):2965-2975. PubMed ID: 30255178
[TBL] [Abstract][Full Text] [Related]
31. SIWV tetrapeptide and ROS-responsive prodrug conjugate for advanced glioblastoma therapy.
Park YK; Jangili P; Zi S; Kang RH; Kim D; Kim JS
Chem Commun (Camb); 2022 Sep; 58(78):10941-10944. PubMed ID: 36082694
[TBL] [Abstract][Full Text] [Related]
32. ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage.
Peng X; Gandhi V
Ther Deliv; 2012 Jul; 3(7):823-33. PubMed ID: 22900465
[TBL] [Abstract][Full Text] [Related]
33. Development of LC-HRMS methods for evaluation of metabolic conversion of 5-fluorocytosine at GDEPT procedure.
Skvara P; Durinikova E; Grabicová K; Mordacikova E; Matuskova M; Vojs Stanova A
J Pharm Biomed Anal; 2021 Sep; 203():114168. PubMed ID: 34089981
[TBL] [Abstract][Full Text] [Related]
34. A Smart Theranostic Prodrug System Activated by Reactive Oxygen Species for Regional Chemotherapy of Metastatic Cancer.
Liu L; Liu F; Liu D; Yuan W; Zhang M; Wei P; Yi T
Angew Chem Int Ed Engl; 2022 Mar; 61(12):e202116807. PubMed ID: 35068033
[TBL] [Abstract][Full Text] [Related]
35. Enzyme/prodrug-based tumor vaccination: all politics (and immunity) are local.
Morris JC
J Natl Cancer Inst; 1999 Dec; 91(23):1986-9. PubMed ID: 10580014
[No Abstract] [Full Text] [Related]
36. Monitoring gene therapy with cytosine deaminase: in vitro studies using tritiated-5-fluorocytosine.
Haberkorn U; Oberdorfer F; Gebert J; Morr I; Haack K; Weber K; Lindauer M; van Kaick G; Schackert HK
J Nucl Med; 1996 Jan; 37(1):87-94. PubMed ID: 8544010
[TBL] [Abstract][Full Text] [Related]
37. ROS-responsive and multifunctional anti-Alzheimer prodrugs: Tacrine-ibuprofen hybrids via a phenyl boronate linker.
Liu Z; Zhang B; Xia S; Fang L; Gou S
Eur J Med Chem; 2021 Feb; 212():112997. PubMed ID: 33189440
[TBL] [Abstract][Full Text] [Related]
38.
Li Z; Wang Y; Liu M; Pan Y; Ni Z; Min Q; Wang B; Ke H; Ji X
J Med Chem; 2023 Nov; 66(21):14583-14596. PubMed ID: 37909153
[TBL] [Abstract][Full Text] [Related]
39. Photodynamic therapy-driven induction of suicide cytosine deaminase gene.
Bil J; Wlodarski P; Winiarska M; Kurzaj Z; Issat T; Jozkowicz A; Wegiel B; Dulak J; Golab J
Cancer Lett; 2010 Apr; 290(2):216-22. PubMed ID: 19822393
[TBL] [Abstract][Full Text] [Related]
40. Selective self-induced stimulus amplification prodrug platform for inhibiting multidrug resistance and lung metastasis.
Xu C; Sun Y; Qi Y; Yu Y; He Y; Hu M; Hu Q; Wu T; Zhang D; Shang L; Deng H; Zhang Z
J Control Release; 2018 Aug; 284():224-239. PubMed ID: 29958912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
